RBC Capital downgrades Kymera Therapeutics to Sector Perform
RBC Capital analyst Brian Abrahams downgraded Kymera Therapeutics from Outperform to Sector Perform and raised the price target to $115 from $106.

*this image is generated using AI for illustrative purposes only.
RBC Capital analyst Brian Abrahams downgraded Kymera Therapeutics from Outperform to Sector Perform and raised the price target to $115 from $106. The adjustment reflects a revised outlook on the stock despite the increased valuation target.
Rating and Price Target Changes
The downgrade moves the stock's rating from Outperform to Sector Perform. Simultaneously, the price target was increased, indicating a revised expectation for the stock's performance.
| Metric | Previous Value | New Value |
|---|---|---|
| Rating | Outperform | Sector Perform |
| Price Target | $106 | $115 |
What specific factors led to the downgrade despite the raised price target?
How might this rating change influence investor sentiment towards Kymera Therapeutics?
What are the potential risks or opportunities that could impact the stock's future performance?






























